Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC-90001
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CC-90001 is an orally bioavailable, selective, small-molecule inhibitor of c-Jun N-terminal kinase 1 (JNK1; also known as mitogen-activated protein kinase 8 or MAPK8), with a strong bias for JNK1 over JNK2. It is a second-generation JNK inhibitor developed for its potential antineoplastic, anti-inflammatory, and antifibrotic activities. By inhibiting the activity of JNK1, CC‑90001 disrupts MAPK-mediated signaling pathways involved in cell proliferation, migration, invasion, and fibrosis. This mechanism may induce cell cycle arrest and apoptosis in cancer cells and reduce fibrotic processes in diseases such as idiopathic pulmonary fibrosis (IPF). The drug has been investigated primarily for IPF in phase 2 clinical trials[1][4][5][6][7].
- Other names
- 1403859-14-2JD5ZWE631KJD-5ZWE631KJD 5ZWE631KCHEMBL4847106CHEMBL-4847106CHEMBL 4847106
02
Targets
JNK (Mitogen-activated protein kinase kinase kinase family)SLC47A1 (Multidrug and toxin extrusion transporter 1)MATE2-K (Multidrug and toxin extrusion protein 2)SLC22A8 (Organic anion transporter 3)OCT2 (Organic cation transporter 2)UGT1A1 (UDP-glucuronosyltransferase 1A1)UGT1A4 (UDP-glucuronosyltransferase 1A4)UGT1A9 (UDP-glucuronosyltransferase 1A9)JUN (Transcription factor Jun)
Beyond the preview
Go deeper on CC-90001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC-90001.